Nationwide Fund Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-50,732
| Closed | -$360K | – | 2884 |
|
|
2017
Q3 | $360K | Buy |
50,732
+4,714
| +10% | +$33.5K | ﹤0.01% | 2346 |
|
|
2017
Q2 | $333K | Hold |
46,018
| – | – | ﹤0.01% | 2390 |
|
|
2017
Q1 | $283K | Sell |
46,018
-3,622
| -7% | -$22.3K | ﹤0.01% | 2443 |
|
|
2016
Q4 | $291K | Sell |
49,640
-2,370
| -5% | -$13.9K | ﹤0.01% | 2446 |
|
|
2016
Q3 | $276K | Hold |
52,010
| – | – | ﹤0.01% | 2471 |
|
|
2016
Q2 | $344K | Sell |
52,010
-13,858
| -21% | -$91.7K | ﹤0.01% | 2346 |
|
|
2016
Q1 | $308K | Sell |
65,868
-2,857
| -4% | -$13.4K | ﹤0.01% | 2323 |
|
|
2015
Q4 | $347K | Buy |
68,725
+1,749
| +3% | +$8.83K | ﹤0.01% | 2291 |
|
|
2015
Q3 | $236K | Hold |
66,976
| – | – | ﹤0.01% | 2480 |
|
|
2015
Q2 | $668K | Sell |
66,976
-7,101
| -10% | -$70.8K | ﹤0.01% | 2083 |
|
|
2015
Q1 | $943K | Buy |
74,077
+4,638
| +7% | +$59K | ﹤0.01% | 1917 |
|
|
2014
Q4 | $983K | Sell |
69,439
-903
| -1% | -$12.8K | ﹤0.01% | 1824 |
|
|
2014
Q3 | $967K | Buy |
70,342
+54
| +0.1% | +$742 | ﹤0.01% | 1849 |
|
|
2014
Q2 | $1.08M | Sell |
70,288
-230,293
| -77% | -$3.54M | ﹤0.01% | 1813 |
|
|
2014
Q1 | $5.12M | Buy |
300,581
+85,642
| +40% | +$1.46M | 0.02% | 855 |
|
|
2013
Q4 | $2.78M | Buy |
214,939
+149,954
| +231% | +$1.94M | 0.01% | 1278 |
|
|
2013
Q3 | $656K | Buy |
64,985
+3,283
| +5% | +$33.1K | ﹤0.01% | 2079 |
|
|
2013
Q2 | $461K | Buy |
+61,702
| New | +$461K | ﹤0.01% | 2051 |
|